"ErbB Receptors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of structurally-related cell-surface receptors that signal through an intrinsic PROTEIN-TYROSINE KINASE. The receptors are activated upon binding of specific ligands which include EPIDERMAL GROWTH FACTORS, and NEUREGULINS.
| Descriptor ID |
D066246
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.009 D12.776.543.750.630.009 D12.776.543.750.750.400.074
|
| Concept/Terms |
ErbB Receptors- ErbB Receptors
- Receptors, ErbB
- Receptors, Epidermal Growth Factor-Urogastrone
- Receptors, Epidermal Growth Factor Urogastrone
- Receptors, Epidermal Growth Factor
- EGF Receptors
- Receptors, EGF
- Epidermal Growth Factor Receptor Family Proteins
- HER Family Receptors
- Family Receptors, HER
- Receptors, HER Family
- Erb-b2 Receptor Tyrosine Kinases
- Erb b2 Receptor Tyrosine Kinases
|
Below are MeSH descriptors whose meaning is more general than "ErbB Receptors".
Below are MeSH descriptors whose meaning is more specific than "ErbB Receptors".
This graph shows the total number of publications written about "ErbB Receptors" by people in this website by year, and whether "ErbB Receptors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 |
| 1997 | 2 | 0 | 2 |
| 1998 | 1 | 1 | 2 |
| 1999 | 1 | 2 | 3 |
| 2000 | 3 | 2 | 5 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 1 | 5 | 6 |
| 2004 | 3 | 3 | 6 |
| 2005 | 9 | 6 | 15 |
| 2006 | 10 | 5 | 15 |
| 2007 | 8 | 8 | 16 |
| 2008 | 9 | 4 | 13 |
| 2009 | 11 | 4 | 15 |
| 2010 | 12 | 4 | 16 |
| 2011 | 7 | 7 | 14 |
| 2012 | 9 | 5 | 14 |
| 2013 | 7 | 3 | 10 |
| 2014 | 12 | 10 | 22 |
| 2015 | 11 | 10 | 21 |
| 2016 | 7 | 8 | 15 |
| 2017 | 8 | 6 | 14 |
| 2018 | 6 | 16 | 22 |
| 2019 | 1 | 7 | 8 |
| 2020 | 0 | 9 | 9 |
| 2021 | 2 | 12 | 14 |
| 2022 | 0 | 10 | 10 |
| 2023 | 0 | 9 | 9 |
| 2024 | 4 | 2 | 6 |
| 2025 | 0 | 10 | 10 |
To return to the timeline,
click here.
Below are the most recent publications written about "ErbB Receptors" by people in Profiles.
-
Clinical Significance of MTAP Deletions and Their Overlap With Concurrent Oncogenic Driver Alterations Including EGFR in NSCLC. J Thorac Oncol. 2026 03; 21(3):103520.
-
Bridging EGFR/TGF-ß Signaling to Bypass Resistance to Immune Checkpoint Blockade. Clin Cancer Res. 2025 Nov 14; 31(22):4617-4619.
-
Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases. J Thorac Oncol. 2026 03; 21(3):103505.
-
Small Cell Transformation of EGFR-Mutant NSCLC Treated with Tyrosine Kinase Inhibition. Curr Oncol. 2025 Oct 03; 32(10).
-
Neuropeptide adrenomedullin remodels stemness and macrophage dynamics in glioblastoma. Cell Rep. 2025 10 28; 44(10):116342.
-
Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024. Cancer. 2025 Sep 01; 131(17):e70060.
-
Current paradigm of EGFRins20 in non-small cell lung cancer: A long way forward. Med. 2025 09 12; 6(9):100803.
-
The dark side of radiotherapy. Cancer Cell. 2025 Aug 11; 43(8):1385-1389.
-
Radiation-induced amphiregulin drives tumour metastasis. Nature. 2025 07; 643(8072):810-819.
-
Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study. Lung Cancer. 2025 04; 202:108417.